Page URL:

NHS will fund gene therapy for bubble boy syndrome

30 October 2017
Appeared in BioNews 924

The UK's National Institute for Health and Care Excellence (NICE) has approved a gene therapy for children born with a rare disorder that leaves them without a functioning immune system.

The Strimvelis treatment for ADA-SCID (adenosine deaminase deficiency, severe combined immunodeficiency) involves removing stem cells from the patient's bone marrow, and altering them to contain a working copy of the faulty gene, before injecting them back into the patient.

'This means that children born with ADA-SCID will now have a better chance of being able to lead as near normal a life as possible, going to school, mixing with friends, free from the constant threat of getting a potentially life-threatening infection,' said Professor Carole Longson, director of the Centre for Health Technology assessment at NICE.

In ADA-SCID, a single gene mutation prevents the development of mature immune cells. Children with the condition are susceptible to multiple infections and without treatment are unlikely to reach school age. It is colloquially called 'bubble boy' syndrome because affected children sometimes have to live in sterile chambers to prevent contact with pathogens.

The standard treatment is a bone-marrow transplant, and this is still the recommended treatment where a good match is available. NICE now recommends that Strimvelis be made available on the NHS in cases where no suitable donor can be found.

Because the treated cells are the patient's own, rejection is not an issue.

The cost of the drug, developed by GlaxoSmithKline, is 594,000 euros (£530,000). However, NICE ruled that it is cost-effective, in part because one dose is expected to last the patient's lifetime.

Currently Strimvelis is only available in the Milan hospital where it was first developed, as the stem cells are too short-lived outside the body to be transported to other medical facilities. 

Britain backs GSK's gene therapy for 'bubble boy' syndrome
Reuters |  23 October 2017
GSK picks up NICE recommendation for Strimvelis, a €594,000 gene therapy
Fierce Pharma |  23 October 2017
NHS to fund gene therapy for 'bubble babies'
The Telegraph |  23 October 2017
NICE approves gene therapy for rare ‘bubble baby syndrome’
NICE |  23 October 2017
25 October 2021 - by James Moore 
Gene therapy given to children born with a deadly immune disease remains safe and effective ten years on, researchers report...
17 May 2021 - by Joseph Hamilton 
An experimental gene therapy successfully treated 96 percent of children born with no immune system...
28 October 2019 - by Dr Rosie Morley 
The Bill and Melinda Gates Foundation has teamed up with the National Institutes of Health (NIH), the US national science funding body, to pledge US$100 million each over four years towards development of gene therapies for HIV and sickle cell anaemia...
29 April 2019 - by Dr Helen Robertson 
Infants born with a severe immunodeficiency disorder have been successfully treated in a new gene therapy trial...
20 November 2017 - by Jen Willows 
A new clinical trial in California marks the first time that genome editing has been used inside the body, rather than on cells such as blood or skin which can be extracted, edited outside the body, and then replaced...
11 April 2016 - by Rebecca Carr 
A gene therapy for children with a rare but life-threatening genetic disorder that severely weakens the immune system has been recommended for approval by the European Medicines Agency...
13 October 2014 - by Dr James Heather 
Gene therapy to treat children with 'bubble boy syndrome' seems to be both safe and effective, a study published in the New England Journal of Medicine has found...
7 January 2008 - by Stuart Scott 
A boy enrolled on a pioneering gene therapy trial has developed leukaemia, his doctors based at London's Great Ormond Street Hospital have announced. The three-year-old was of one of 10 patients treated for X-SCID: a genetic disorder whereby a mutation in the IL2RG gene leaves carriers without...
27 April 2006 - by BioNews 
Replacement genes used to treat an inherited immune disorder could trigger cancer, new research carried out on rodents suggests. The study, published in the journal Nature, shows that treating mice with a normal copy of the gene defective in X-linked severe combined immune deficiency (X-SCID) results in cancer of the...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.